Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Merck's cancer drug...

    Merck's cancer drug Keytruda notches another trial success

    Written by Ruby Khatun Khatun Published On 2018-05-25T09:30:57+05:30  |  Updated On 25 May 2018 9:30 AM IST

    Merck & Co said its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.


    Keytruda, already approved for other types of cancer, is being studied in a late-stage trial as a first-line treatment, in combination with chemotherapy, for metastatic squamous non-small cell lung cancer (sNSCLC) patients.


    Merck said the combination therapy met its main trial goals when compared to patients who were on chemotherapy alone, according to an interim analysis.


    The company’s shares were up 1 percent at $59.04 in midday trading.


    Earlier this month, Merck reported data from an interim analysis of the trial that met a secondary goal of overall response rate, or the portion of patients with a reduction in tumor size.


    Merck had submitted a marketing application to the U.S. Food and Drug Administration for the sNSCLC indication recently.


    “We doubted that Merck would submit the study for FDA approval based on overall response rate if it did not have confidence in the primary endpoints,” said BMO Capital Markets analyst Alex Arfaei.





    Analysts were looking for the latest data to support the company’s application for an expanded approval.



    Vamil Divan from Credit Suisse said, “We already knew Keytruda showed a benefit on overall response rate, but prolonging survival is obviously what matters.”


    Credit Suisse estimates that the areas in which Keytruda has now shown positive data represent a market opportunity of $6.6 billion in first-line non-small cell lung cancer in the United States.


    Keytruda is the only immunotherapy approved in the United States to treat lung cancer patients who have not received prior treatment.


    Merck has been expanding its position into the lung cancer market through Keytruda. Also jockeying for a piece of the lucrative market are drugmakers Bristol-Myers Squibb, Roche and AstraZeneca, which are advancing their rival immunotherapies.




    Merck said the new data will be shared with the U.S. Food and Drug Administration as part of its push to expand the drug’s label and would be presented at an upcoming medical conference, the company said.




    (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)




    cancercancer drugchemotherapyKeytrudalung cancerMerckmetastatic squamous non-small cell lung cancerU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok